What You Should Know:
– Manifold, an AI-powered clinical data platform, announced that Morehouse School of Medicine (MSM) will leverage their platform to modernize cancer genomics data analysis and improve collaboration among multidisciplinary stakeholders.
– With Manifold, the Institute of Translational Genomic Medicine (ITGM) at MSM is building a modern data foundation to accelerate cancer research—integrating multimodal sources like clinical outcomes, genomics, survey, and geospatial data, making them accessible for exploration by researchers with a wide range of coding experience.
Enhancing Breast Cancer Research with AI-Driven Data Integration in Underrepresented Populations
As healthcare data continues to grow in volume and complexity, legacy technologies struggle to accommodate the diverse range of data modalities, such as digital pathology slides and unstructured medical notes. These outdated tools lack the necessary capabilities to support advanced analytical techniques like machine learning. Manifold’s cutting-edge technology will empower MSM with AI-powered data analysis, enabling the integration of varied data types into a cohesive platform, thereby unlocking previously inaccessible insights.
The initial focus of Dr. Davis and the research team will be advancing breast cancer research among African ancestry patients enrolled in the Polyethnic 1000 study at the New York Genome Center. This project, funded by The New York Community Trust, aims to integrate geospatial, clinical, and genomic data to uncover intricate details about the molecular characteristics of cancer in these underrepresented communities.
Manifold’s Cancer Observational Study Management solution will be employed to re-engage the patient cohort through targeted surveys, collecting additional information on lifestyle, environmental influences, and health outcomes. This integrated approach will provide a comprehensive understanding of how cancer manifests in these populations, contributing to more equitable healthcare outcomes.
“Connecting this data represents a transformative shift in how we understand cancer disparities and accelerates the progress we can achieve as a community,” said Dr. Melissa Davis, ITGM Director. “Manifold’s partnership helps us advance our mission to provide genomic research capacity across MSM as well as to increase knowledge of genetic variation across the African diaspora and its impact on health and disease.”
